US revenue increased 43% to $12.9 billion, fueled by a 50% jump in volume, partially offset by a 7% decline in realized prices
The findings, based on an exploratory analysis, indicate that CD47 expression may predict which patients benefit most from the therapy
The facility is dedicated to breakthrough innovations in laboratory instruments that detect infectious diseases, cancer, and blood disorders
_Limited_256_384.jpg)
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
On a proforma basis in Q3 FY26, revenues grew by 15% YoY to Rs. 2,366 Cr and operating EBITDA increased by 22% YoY to Rs. 503 Cr
Growth across inorganic & organic chemicals, fertilisers, pharmaceuticals, cosmetics, soaps and detergents
The Chennai facility will manufacture high-quality medical tubing for neurovascular and cardiovascular applications, including balloon catheters and other minimally invasive devices
Hongene will focus on developing and scaling production of key capping reagents—essential components of mRNA therapeutics—emphasizing accessibility, transparency, and global deployment
The EU approval of DAWNZERA is an important milestone that reflects our ongoing commitment to bring this innovative medicine to people in need across the globe
Subscribe To Our Newsletter & Stay Updated
